GSK’s Bepirovirsen Demonstrates Statistically Significant Functional Cure Rates in Chronic Hepatitis B
GlaxoSmithKline plc announced positive results from the B-Well 1 and B-Well 2 pivotal Phase III clinical trials evaluating bepirovirsen (GSK3228836), an investigational antisense oligonucleotide (ASO) designed as the first-in-class finite-duration therapy capable of achieving functional cure in patients with chronic hepatitis B
